Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group (Q33584368)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

phase I clinical trial

0 references

0 references

focal segmental glomerulosclerosis

1 reference

based on heuristic

inferred from title

Howard Trachtman

object named as

Howard Trachtman

13

0 references

Jeffrey B. Kopp

object named as

Jeffrey B Kopp

11

0 references

Virginia J Savin

8

object named as

Virginia Savin

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Daniel C. Cattran

12

object named as

Daniel Cattran

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Debbie S Gipson

2

object named as

Debbie S Gipson

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Melanie S Joy

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Leslie Powell

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Jacqueline MacHardy

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

J Charles Jennette

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Suzanne Vento

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Cynthia Pan

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Allison Eddy

9

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Agnes B Fogo

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

22 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

American Journal of Kidney Diseases

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

50-60

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Investigation of the cause of death in a gene-therapy trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Immunoregulatory role of TNFalpha in inflammatory kidney diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Many cytokines are very useful therapeutic targets in disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Mechanism-based concepts of size and maturity in pharmacokinetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

In situ upregulation of IL-10 reflects the activity of human glomerulonephritides.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

21 June 2018

Successful anti-TNFalpha treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

31 October 2018

Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

31 October 2018

Ganoderma lucidum suppresses endothelial cell cytotoxicity and proteinuria in persistent proteinuric focal segmental glomerulosclerosis (FSGS) nephrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

31 October 2018

Implications of serum TNF-beta and IL-13 in the treatment response of childhood nephrotic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

31 October 2018

Use of pentoxifylline in membranous nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

31 October 2018

Autoimmune Diseases Induced by TNF-Targeted Therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804955

31 October 2018

[Tumor necrosis factor (TNF) and interleukin-6 (IL-6) in patients with glomerulonephritis]

1 reference

https://pubmed.ncbi.nlm.nih.gov/19932542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide

1 reference

https://pubmed.ncbi.nlm.nih.gov/19932542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal macrophage activation and Th2 polarization precedes the development of nephrotic syndrome in Buffalo/Mna rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/19932542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab and nephrotic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19932542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T-lymphocyte populations and cytokines in childhood nephrotic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19932542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19932542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor-α production from mononuclear cells in nephrotic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19932542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor-alpha blocking agent as a treatment for nephrotic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19932542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protein clearances and selectivity determinations in childhood nephrosis: a reappraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/19932542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/19932542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibitory effect of Tripterygium wilfordii multiglycoside on increased glomerular albumin permeability in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/19932542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1053/J.AJKD.2009.08.019

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33584368&oldid=2023137294"